Highlights Cellectar Biosciences, Inc.

Equities

CLRB

US15117F8077

Real-time Estimate Cboe BZX Other stock markets 09:33:33 27/06/2024 pm IST			5-day change	1st Jan Change
2.535 ^USD	-12.28%		-8.57%	-7.58%

29/05	Cellectar Biosciences, Inc. and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis fungoides	CI
14/05	Transcript : Cellectar Biosciences, Inc., Q1 2024 Earnings Call, May 14, 2024

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Cellectar Biosciences, Inc. and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis fungoides	29/05	CI
Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Cellectar Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
Cellectar Biosciences, Inc. Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer	04/03	CI
Cellectar Biosciences, Inc. Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1B Clinical Study	30/01	CI
Cellectar Biosciences, Inc. Reports Complete Central Nervous System Clearance in Relapsed/Refractory Waldenstrom?s Macroglobulinemia Patient	22/01	CI
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy for Solid Tumors and Releases Promising Preclinical Data	16/01	CI
Cellectar Biosciences Partners with MiBA to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting	11/01	CI
Global markets live: Merck, Honda, Novartis, Boeing, Nvidia...	08/01
Cellectar's blood cancer therapy succeeds in late-stage study	08/01	RE
Cellectar's blood cancer therapy succeeds in trial	08/01	RE
Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom's Macroglobulinemia	08/01	CI
Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation	19/12	CI
Cellectar Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11	CI
Cellectar Biosciences, Inc. to Release Top-Line Data from Wm Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024	02/11	CI
Cellectar Biosciences, Florida Cancer Specialists & Research Institute to Collaborate on Lymphoma Research	25/23/25	MT
Cellectar Biosciences, Inc. Receives European Medicines Agency Priority Medicines Designation for Iopofosine for Waldenstrom's Macroglobulinemia	18/23/18	CI
Cellectar Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI
Cellectar Biosciences, Inc. Announces Data from its Ongoing Study of iopofosine I 131 in Multiple Myeloma	30/23/30	CI
Cellectar Biosciences, Inc. Provides an Update for Its iopofosine I 131 Clinical Program and Guidance Related to Its Proprietary Phospholipidether Drug Conjugate Platform	12/23/12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cellectar Biosciences, Inc.

Equities

CLRB

US15117F8077

Highlights

Filters